Novo Nordisk’s newly approved oral GLP-1 weight loss therapy garnered over 18,000 U.S. prescriptions in its first week on the market, signaling robust patient uptake. This launch success preceded a 26% stock rebound in early 2026, following a 41% decline in 2025. Analysts note that, with a price/earnings ratio near 17, the shares trade at a significant discount to peers and could see further appreciation as the company leverages its first-mover advantage in the oral obesity segment.

In the first nine months of 2025, Novo Nordisk increased U.S. promotional outlays to approximately $316 million for Wegovy and $169 million for Ozempic, representing year-over-year increases of 54% and 44% respectively. Total advertising investment of $485 million more than doubled rival Eli Lilly’s combined spend on Zepbound and Mounjaro. Despite this, Eli Lilly commanded roughly 60% of the U.S. obesity drug market last year, underpinned by clinical trial data showing 47% greater weight loss on Zepbound versus Wegovy users in head-to-head analysis.

Novo Nordisk faces a U.S. class action accusing it of orchestrating a reverse-payment agreement to delay generic competition for its diabetes injection pen Victoza. Plaintiffs contend that a deal with Teva postponed generic entry until mid-2024, preserving over $5 billion in annual U.S. Victoza sales and shifting patients onto Ozempic. The suit claims the arrangement blocked other generics for at least 16 months, forcing healthcare purchasers to pay supracompetitive prices and seeks recovery of hundreds of millions in alleged overcharges.

Despite operational strengths—first-mover lead in obesity treatments, robust cash flow and anticipated seasonal Q4 sales lift—Novo Nordisk’s high forward valuation (PEG ratio around 3.3 versus a 1.8 sector median) and stretched technical indicators prompt a Hold recommendation from several brokerages. Consensus revenue growth forecasts of mid-teens may prove conservative given historical double-digit performance, but potential profit-taking and elevated marketing investment pose near-term headwinds ahead of the upcoming quarterly report.